QuidelOrtho (QDEL) Projected to Post Earnings on Tuesday

Key Points

• QuidelOrtho is expected to report Q3 2026 results after the market closes on November 3. Analysts project earnings of $0.2023 per share on $627.83 million in revenue; the company’s full-year EPS guidance is $0.65 to $0.90.
• In its most recent quarter, QuidelOrtho reported $0.13 EPS and $630.9 million in revenue, exceeding analyst expectations, while revenue increased 2.8% year over year.
• Investor sentiment remains cautious: analysts assign the stock a consensus “Reduce” rating with a $13.62 target price. Shares recently opened at $13.68, well below their 12-month high of $35.58.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) is expected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.2023 per share and revenue of $627.83 million for the quarter. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Parties may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 5:00 PM ET.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.18. The firm had revenue of $630.90 million for the quarter, compared to analysts' expectations of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The business's revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.12 earnings per share. On average, analysts expect QuidelOrtho to post $0.75 EPS for the current fiscal year and $1.45 EPS for the next fiscal year.

QuidelOrtho Price Performance

Shares of QDEL opened at $13.68 on Tuesday. QuidelOrtho has a twelve month low of $9.92 and a twelve month high of $35.58. The company has a market capitalization of $938.24 million, a P/E ratio of -0.89 and a beta of 0.79. The firm has a 50 day moving average of $12.80 and a 200 day moving average of $16.87. The company has a quick ratio of 0.76, a current ratio of 1.39 and a debt-to-equity ratio of 1.43.

Analyst Upgrades and Downgrades

A number of analysts have commented on QDEL shares. Citigroup lifted their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a "neutral" rating in a report on Wednesday, July 8th. Zacks Research raised QuidelOrtho from a "strong sell" rating to a "hold" rating in a research report on Friday, October 9th. JPMorgan Chase & Co. increased their price objective on QuidelOrtho from $11.00 to $12.00 and gave the company an "underweight" rating in a research report on Wednesday, July 1st. Jefferies Financial Group reiterated a "hold" rating on shares of QuidelOrtho in a report on Monday, June 29th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of QuidelOrtho in a research report on Thursday, October 15th. Four investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus target price of $13.62.

About QuidelOrtho

QuidelOrtho Corporation NASDAQ: QDEL is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.